Stock Events

Stock Events

Valirx 

€0
0
-€0-0% Friday 13:48

Statistics

Day High
0
Day Low
0
52W High
0.01
52W Low
0
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10JunExpected
Q2 2023
Next
-0.01
0.32
0.65
0.99
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EAJF.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Astrazeneca
AZN.LSE
Mkt Cap236.19B
GSK
GSK.LSE
Mkt Cap86.96B
Bristol-Myers Squibb
BMY
Mkt Cap119.69B
Bristol Myers Squibb, a global biopharmaceutical company, focuses on discovering, developing, and delivering innovative medicines for cancer and other diseases, aligning with Valirx's mission.
Pfizer
PFE
Mkt Cap153.13B
Pfizer's broad range of oncology and biopharmaceutical products makes it a competitor to Valirx, especially in the development of cancer treatments.
Merck
MRK
Mkt Cap300.2B
Merck & Co.'s strong focus on cancer research and therapies, including immunotherapy and targeted treatments, places it in direct competition with Valirx.
Roche
RHHBY
Mkt Cap322.3B
Roche Holding AG, with its extensive portfolio in oncology and personalized healthcare, competes in the same space as Valirx, particularly in cancer treatment innovations.
Novartis
NVS
Mkt Cap297.35B
Novartis AG, known for its leadership in healthcare and significant investment in research and development in oncology, competes with Valirx in the cancer treatment arena.
Abbvie
ABBV
Mkt Cap367.8B
AbbVie's focus on developing advanced therapies for complex diseases, including cancer, makes it a competitor to Valirx, especially in the area of innovative treatment options.
AMGEN
AMGN
Mkt Cap189.22B
Amgen, with its focus on human therapeutics and strong pipeline in oncology, competes with Valirx in the development of cancer treatments and therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.17B
Regeneron Pharmaceuticals, known for its innovative biotechnology and medical research in oncology, competes with Valirx in the quest to develop novel cancer therapies.

About

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19; and CLX001, a peptide nanoparticle formulation that is in pre-clinical trial for destruction of cancer cells. The company also develops and commercializes oncology assets in the veterinary market. It has an agreement with University of Dundee. ValiRx plc was incorporated in 2000 and is based in London, the United Kingdom.
Show more...
CEO
ISIN
GB00BLH13C52

Listings

STU
DE
EAJF.STU
F
DE
EAJF.F
LSE
GB
VAL.LSE

0 Comments

Share your thoughts

FAQ

What is Valirx stock price today?▼
The current price of EAJF.STU is €0 EUR — it has decreased by -0% in the past 24 hours. Watch Valirx stock price performance more closely on the chart.
What is Valirx stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Valirx stocks are traded under the ticker EAJF.STU.
Is Valirx stock price growing?▼
EAJF.STU stock has risen by +0% compared to the previous week, the month change is a -0% fall, over the last year Valirx has showed a -0% decrease.
When is the next Valirx earnings date?▼
Valirx is going to release the next earnings report on June 10, 2026.
What were Valirx earnings last quarter?▼
EAJF.STU earnings for the last quarter are -0.01 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
In which sector is Valirx located?▼
Valirx operates in the Other sector.
When did Valirx complete a stock split?▼
Valirx has not had any recent stock splits.